表紙
市場調查報告書
商品編碼
1027198

急性冠狀動脈症候群(ACS)治療藥市場:各醫藥品、類型、治療方法、診斷、終端用戶、地區 -至2026年的市場預測 - 新型冠狀病毒感染疾病(COVID-19)的累積性影響

Acute Coronary Syndrome Therapeutic Market Research Report by Drug, by Type, by Treatment, by Diagnosis, by End User, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日期: | 出版商: 360iResearch LLP | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球急性冠狀動脈症候群(ACS)治療藥的市場規模,預計2020年價值75億8,226萬美元,2021年達到80億9,256萬美元。還有預計至2026年以7.06%的年複合成長率成長,至2026年達到114億2,280萬美元。

本報告提供全球急性冠狀動脈症候群(ACS)治療藥市場調查,各醫藥品、類型、治療方法、診斷、終端用戶的市場規模的變化與預測,各地區的詳細趨勢,市場成長要素及阻礙因素,市場機會,課題,新型冠狀病毒感染疾病(COVID-19)的累積性影響,市場佔有率,競爭情形,主要企業簡介等彙整資訊。

目錄

第1章 序文

第2章 調查手法

第3章 摘要整理

  • 簡介
  • 市場預測
  • 市場預測:各類醫藥品
  • 市場預測:各類型
  • 市場預測:各治療法
  • 市場預測:各診斷
  • 市場預測:各終端用戶
  • 市場預測:各地區
  • 競爭企業預測

第4章 市場概要

  • 簡介
  • 新型冠狀病毒感染疾病(COVID-19)的累積性影響

第5章 市場洞察

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • 波特的五力分析
    • 新加入業者的威脅
    • 替代品的威脅
    • 客戶談判力
    • 供給企業談判力
    • 產業的競爭

第6章 急性冠狀動脈症候群(ACS)治療藥市場:各類醫藥品

  • 簡介
  • 降壓藥
  • 抗血栓劑
  • Statin

第7章 急性冠狀動脈症候群(ACS)治療藥市場各類型

  • 非ST上升型心肌梗塞
  • ST上升型心肌梗塞
  • 管瓶不穩定心絞痛

第8章 急性冠狀動脈症候群(ACS)治療藥市場:各治療法

  • 簡介
  • 藥物治療
    • 心絞痛治療藥
    • 抗凝固劑
    • 抗血小板藥
  • 出院後的治療
  • 醫院前的照護
  • 再灌流療法

第9章 急性冠狀動脈症候群(ACS)治療藥市場:各診斷

  • 簡介
  • 血液檢驗
  • CT血管造影術
  • 冠動脈攝影術
  • 心臟超音波圖
  • 成像

第10章 急性冠狀動脈症候群(ACS)治療藥市場:各終端用戶

  • 簡介
  • 學術機構
  • 診斷中心
  • 醫院、診所

第11章 南北美洲的急性冠狀動脈症候群(ACS)治療藥市場

  • 簡介
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章 亞太地區的急性冠狀動脈症候群(ACS)治療藥市場

  • 簡介
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 泰國

第13章 歐洲、中東、非洲的急性冠狀動脈症候群(ACS)治療藥市場

  • 簡介
  • 法國
  • 德國
  • 義大利
  • 荷蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合大公國
  • 英國

第14章 競爭情形

  • FPNV定位矩陣
    • 象限
    • 事業策略
    • 產品的滿意度
  • 市場排行榜分析
  • 主要企業的市場佔有率分析
  • 競爭模式
    • 合併、收購
    • 契約、合作、夥伴關係
    • 新產品銷售、強化
    • 投資、資金籌措
    • 獎、獎勵、擴大

第15章 企業簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Arena Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Gilead Sciences, Inc.,
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • XOMA Corporation

第16章 附錄

目錄
Product Code: MRR-B85ACE4D9530

The Global Acute Coronary Syndrome Therapeutic Market size was estimated at USD 7,582.26 Million in 2020 and expected to reach USD 8,092.56 Million in 2021, at a Compound Annual Growth Rate (CAGR) 7.06% to reach USD 11,422.80 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Acute Coronary Syndrome Therapeutic to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Drug, the Acute Coronary Syndrome Therapeutic Market was studied across Antihypertensive, Antithrombotic, and Statins.
  • Based on Type, the Acute Coronary Syndrome Therapeutic Market was studied across Non-ST-elevation Myocardial Infarction, ST-elevation Myocardial Infarction, and Vial Unstable Angina.
  • Based on Treatment, the Acute Coronary Syndrome Therapeutic Market was studied across Drug Treatment, Post Discharge Treatment, Prehospital Care, and Reperfusion Therapy. The Drug Treatment is further studied across Antianginal Drug, Anticoagulant, and Antiplatelet Drug.
  • Based on Diagnosis, the Acute Coronary Syndrome Therapeutic Market was studied across Blood Tests, Computerized Tomography Angiogram, Coronary Angiogram, Echocardiogram, and Imaging.
  • Based on End User, the Acute Coronary Syndrome Therapeutic Market was studied across Academic Institutes, Diagnostic Centers, and Hospital & Clinics.
  • Based on Region, the Acute Coronary Syndrome Therapeutic Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Acute Coronary Syndrome Therapeutic Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Acute Coronary Syndrome Therapeutic Market, including AbbVie Inc., Amgen Inc., Arena Pharmaceuticals, Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Gilead Sciences, Inc.,, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and XOMA Corporation.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Acute Coronary Syndrome Therapeutic Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Acute Coronary Syndrome Therapeutic Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Acute Coronary Syndrome Therapeutic Market?
  • 4. What is the competitive strategic window for opportunities in the Global Acute Coronary Syndrome Therapeutic Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Acute Coronary Syndrome Therapeutic Market?
  • 6. What is the market share of the leading vendors in the Global Acute Coronary Syndrome Therapeutic Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Acute Coronary Syndrome Therapeutic Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Outlook
  • 3.4. Type Outlook
  • 3.5. Treatment Outlook
  • 3.6. Diagnosis Outlook
  • 3.7. End User Outlook
  • 3.8. Region Outlook
  • 3.9. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased cases of atherosclerosis (myocardial infarction) and unstable angina
      • 5.1.1.2. Growing aging population and poor immune systems
      • 5.1.1.3. Increased pharmaceutical R&D investment and introduction of innovative drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Obstruction due to less number of approved drugs for the treatment of acute coronary syndrome
    • 5.1.3. Opportunities
      • 5.1.3.1. Reperfusion of the myocardium and prevent reinfarction in order to promote patient survival
      • 5.1.3.2. Extensive pipeline drugs with properties, such as high patient compliance and improved safety
      • 5.1.3.3. Improving health care infrastructure and government reimbursement programs
    • 5.1.4. Challenges
      • 5.1.4.1. Cost and formulation
  • 5.2. Porters Five Forces Analysis
    • 5.2.1. Threat of New Entrants
    • 5.2.2. Threat of Substitutes
    • 5.2.3. Bargaining Power of Customers
    • 5.2.4. Bargaining Power of Suppliers
    • 5.2.5. Industry Rivalry

6. Acute Coronary Syndrome Therapeutic Market, by Drug

  • 6.1. Introduction
  • 6.2. Antihypertensive
  • 6.3. Antithrombotic
  • 6.4. Statins

7. Acute Coronary Syndrome Therapeutic Market, by Type

  • 7.1. Introduction
  • 7.2. Non-ST-elevation Myocardial Infarction
  • 7.3. ST-elevation Myocardial Infarction
  • 7.4. Vial Unstable Angina

8. Acute Coronary Syndrome Therapeutic Market, by Treatment

  • 8.1. Introduction
  • 8.2. Drug Treatment
    • 8.2.1. Antianginal Drug
    • 8.2.2. Anticoagulant
    • 8.2.3. Antiplatelet Drug
  • 8.3. Post Discharge Treatment
  • 8.4. Prehospital Care
  • 8.5. Reperfusion Therapy

9. Acute Coronary Syndrome Therapeutic Market, by Diagnosis

  • 9.1. Introduction
  • 9.2. Blood Tests
  • 9.3. Computerized Tomography Angiogram
  • 9.4. Coronary Angiogram
  • 9.5. Echocardiogram
  • 9.6. Imaging

10. Acute Coronary Syndrome Therapeutic Market, by End User

  • 10.1. Introduction
  • 10.2. Academic Institutes
  • 10.3. Diagnostic Centers
  • 10.4. Hospital & Clinics

11. Americas Acute Coronary Syndrome Therapeutic Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Acute Coronary Syndrome Therapeutic Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Thailand

13. Europe, Middle East & Africa Acute Coronary Syndrome Therapeutic Market

  • 13.1. Introduction
  • 13.2. France
  • 13.3. Germany
  • 13.4. Italy
  • 13.5. Netherlands
  • 13.6. Qatar
  • 13.7. Russia
  • 13.8. Saudi Arabia
  • 13.9. South Africa
  • 13.10. Spain
  • 13.11. United Arab Emirates
  • 13.12. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
    • 14.1.1. Quadrants
    • 14.1.2. Business Strategy
    • 14.1.3. Product Satisfaction
  • 14.2. Market Ranking Analysis
  • 14.3. Market Share Analysis, By Key Player
  • 14.4. Competitive Scenario
    • 14.4.1. Merger & Acquisition
    • 14.4.2. Agreement, Collaboration, & Partnership
    • 14.4.3. New Product Launch & Enhancement
    • 14.4.4. Investment & Funding
    • 14.4.5. Award, Recognition, & Expansion

15. Company Usability Profiles

  • 15.1. AbbVie Inc.
  • 15.2. Amgen Inc.
  • 15.3. Arena Pharmaceuticals, Inc.
  • 15.4. AstraZeneca PLC
  • 15.5. Baxter International Inc.
  • 15.6. Bayer AG
  • 15.7. Biogen Inc.
  • 15.8. Boehringer Ingelheim International GmbH
  • 15.9. Eli Lilly and Company
  • 15.10. Gilead Sciences, Inc.
  • 15.11. Gilead Sciences, Inc.,
  • 15.12. GlaxoSmithKline PLC
  • 15.13. Johnson & Johnson Services, Inc.
  • 15.14. Merck & Co., Inc.
  • 15.15. Novartis International AG
  • 15.16. Pfizer Inc.
  • 15.17. Teva Pharmaceutical Industries Ltd.
  • 15.18. XOMA Corporation

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY REGION, 2020 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: MARKET DYNAMICS
  • FIGURE 10. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 11. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2020 VS 2026 (%)
  • FIGURE 12. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2020 VS 2026 (USD MILLION)
  • FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2026
  • FIGURE 14. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIHYPERTENSIVE, 2018-2026 (USD MILLION)
  • FIGURE 15. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 16. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTITHROMBOTIC, 2018-2026 (USD MILLION)
  • FIGURE 17. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTITHROMBOTIC, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 18. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY STATINS, 2018-2026 (USD MILLION)
  • FIGURE 19. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY STATINS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 20. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
  • FIGURE 21. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2026
  • FIGURE 23. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY NON-ST-ELEVATION MYOCARDIAL INFARCTION, 2018-2026 (USD MILLION)
  • FIGURE 24. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY NON-ST-ELEVATION MYOCARDIAL INFARCTION, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 25. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ST-ELEVATION MYOCARDIAL INFARCTION, 2018-2026 (USD MILLION)
  • FIGURE 26. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ST-ELEVATION MYOCARDIAL INFARCTION, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 27. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY VIAL UNSTABLE ANGINA, 2018-2026 (USD MILLION)
  • FIGURE 28. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY VIAL UNSTABLE ANGINA, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 29. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2020 VS 2026 (%)
  • FIGURE 30. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2026
  • FIGURE 32. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG TREATMENT, 2018-2026 (USD MILLION)
  • FIGURE 33. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG TREATMENT, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 34. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIANGINAL DRUG, 2018-2026 (USD MILLION)
  • FIGURE 35. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIANGINAL DRUG, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 36. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTICOAGULANT, 2018-2026 (USD MILLION)
  • FIGURE 37. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTICOAGULANT, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 38. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIPLATELET DRUG, 2018-2026 (USD MILLION)
  • FIGURE 39. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIPLATELET DRUG, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 40. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY POST DISCHARGE TREATMENT, 2018-2026 (USD MILLION)
  • FIGURE 41. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY POST DISCHARGE TREATMENT, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 42. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY PREHOSPITAL CARE, 2018-2026 (USD MILLION)
  • FIGURE 43. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY PREHOSPITAL CARE, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 44. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY REPERFUSION THERAPY, 2018-2026 (USD MILLION)
  • FIGURE 45. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY REPERFUSION THERAPY, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 46. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2020 VS 2026 (%)
  • FIGURE 47. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2020 VS 2026 (USD MILLION)
  • FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2026
  • FIGURE 49. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY BLOOD TESTS, 2018-2026 (USD MILLION)
  • FIGURE 50. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY BLOOD TESTS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 51. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY COMPUTERIZED TOMOGRAPHY ANGIOGRAM, 2018-2026 (USD MILLION)
  • FIGURE 52. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY COMPUTERIZED TOMOGRAPHY ANGIOGRAM, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 53. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY CORONARY ANGIOGRAM, 2018-2026 (USD MILLION)
  • FIGURE 54. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY CORONARY ANGIOGRAM, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 55. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ECHOCARDIOGRAM, 2018-2026 (USD MILLION)
  • FIGURE 56. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 57. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY IMAGING, 2018-2026 (USD MILLION)
  • FIGURE 58. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY IMAGING, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 59. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2020 VS 2026 (%)
  • FIGURE 60. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2020 VS 2026 (USD MILLION)
  • FIGURE 61. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2026
  • FIGURE 62. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2026 (USD MILLION)
  • FIGURE 63. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 64. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2026 (USD MILLION)
  • FIGURE 65. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 66. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY HOSPITAL & CLINICS, 2018-2026 (USD MILLION)
  • FIGURE 67. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2020 VS 2026 (USD MILLION)
  • FIGURE 68. AMERICAS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 69. ARGENTINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 70. BRAZIL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 71. CANADA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 72. MEXICO ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 73. UNITED STATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 74. ASIA-PACIFIC ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 75. AUSTRALIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 76. CHINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 77. INDIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 78. INDONESIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 79. JAPAN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 80. MALAYSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 81. PHILIPPINES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 82. SINGAPORE ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 83. SOUTH KOREA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 84. THAILAND ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 85. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 86. FRANCE ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 87. GERMANY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 88. ITALY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 89. NETHERLANDS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 90. QATAR ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 91. RUSSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 92. SAUDI ARABIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 93. SOUTH AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 94. SPAIN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 95. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 96. UNITED KINGDOM ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • FIGURE 97. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: FPNV POSITIONING MATRIX
  • FIGURE 98. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: SHARE, BY KEY PLAYER, 2020
  • FIGURE 99. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG, 2018-2026 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIHYPERTENSIVE, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTITHROMBOTIC, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY STATINS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TYPE, 2018-2026 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY NON-ST-ELEVATION MYOCARDIAL INFARCTION, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ST-ELEVATION MYOCARDIAL INFARCTION, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY VIAL UNSTABLE ANGINA, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY TREATMENT, 2018-2026 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DRUG TREATMENT, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIANGINAL DRUG, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTICOAGULANT, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ANTIPLATELET DRUG, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY POST DISCHARGE TREATMENT, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY PREHOSPITAL CARE, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY REPERFUSION THERAPY, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSIS, 2018-2026 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY COMPUTERIZED TOMOGRAPHY ANGIOGRAM, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY CORONARY ANGIOGRAM, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY IMAGING, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY END USER, 2018-2026 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2026 (USD MILLION)
  • TABLE 30. AMERICAS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 31. ARGENTINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 32. BRAZIL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 33. CANADA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 34. MEXICO ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 35. UNITED STATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 37. AUSTRALIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 38. CHINA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 39. INDIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 40. INDONESIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 41. JAPAN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 42. MALAYSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 43. PHILIPPINES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 44. SINGAPORE ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 45. SOUTH KOREA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 46. THAILAND ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 47. EUROPE, MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 48. FRANCE ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 49. GERMANY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 50. ITALY ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 51. NETHERLANDS ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 52. QATAR ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 53. RUSSIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 54. SAUDI ARABIA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 55. SOUTH AFRICA ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 56. SPAIN ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 57. UNITED ARAB EMIRATES ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 58. UNITED KINGDOM ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE, 2018-2026 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: SCORES
  • TABLE 60. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: BUSINESS STRATEGY
  • TABLE 61. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: PRODUCT SATISFACTION
  • TABLE 62. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: RANKING
  • TABLE 63. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: SHARE, BY KEY PLAYER, 2020
  • TABLE 64. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: MERGER & ACQUISITION
  • TABLE 65. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 66. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 67. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: INVESTMENT & FUNDING
  • TABLE 68. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 69. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET: LICENSE & PRICING